Daniele D'Ambrosio
Actelion
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Daniele D'Ambrosio as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:39 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT02461134 · Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHDActelion · terminated · Chronic Graft Versus Host Disease · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:39 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:39 UTC. The ranking covers the 200 most relevant of 15 PubMed records, and a shared surname and initials can bring in a namesake. All 15 on PubMed
- Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.JAMA Neurol · 2021188 citationsRCR 13.4
- A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.Arthritis Rheum · 2012139 citationsRCR 4.8
- 139 citationsRCR 4.7
- Initial Results of a Multicenter Phase 2 Trial of Stereotactic Ablative Radiation Therapy for Oligometastatic Cancer.Int J Radiat Oncol Biol Phys · 201972 citationsRCR 3.0
- The Effect of 12 Weeks of β-Hydroxy-β-Methyl-Butyrate Supplementation after Liver Transplantation: A Pilot Randomized Controlled Study.Nutrients · 201933 citationsRCR 2.0
- Clinical pharmacology of ponesimod, a selective S1P₁ receptor modulator, after uptitration to supratherapeutic doses in healthy subjects.Eur J Pharm Sci · 201426 citationsRCR 0.9
- Differential effects of ponesimod, a selective S1P1 receptor modulator, on blood-circulating human T cell subpopulations.Immunopharmacol Immunotoxicol · 201524 citationsRCR 0.8
- Three different up-titration regimens of ponesimod, an S1P1 receptor modulator, in healthy subjects.J Clin Pharmacol · 201518 citationsRCR 0.7
- Effects of multiple-dose ponesimod, a selective S1P1 receptor modulator, on lymphocyte subsets in healthy humans.Drug Des Devel Ther · 201614 citationsRCR 0.5
- Modeling clinical efficacy of the S1P receptor modulator ponesimod in psoriasis.J Dermatol Sci · 201813 citationsRCR 0.6